Measles Rash (Rubeola): What Every Patient Should Know

Clinical Overview

Measles (rubeola) is a highly contagious viral infection affecting unvaccinated or under-vaccinated populations, characterized by a distinctive maculopapular exanthem preceded by pathognomonic Koplik spots. The disease causes fever (typically 39-40.5°C), cough, coryza, and conjunctivitis (the "3 Cs") before the rash appears. Though rare in vaccinated populations, measles remains a significant cause of childhood morbidity and mortality globally, with complications including pneumonia (1-6%), encephalitis (1 per 1000 cases), and otitis media (7%). Vitamin A supplementation is critical in managing measles to reduce complications by 23% and mortality by 12%.

Epidemiology

Before MMR vaccine introduction in 1963, measles affected nearly 100% of children by age 12 years. Current incidence in vaccinated populations is <1 case per 100,000 population annually. However, in unvaccinated populations, secondary attack rates reach 90%, making measles the most contagious human virus. Global measles deaths exceed 100,000 annually, primarily affecting children <5 years in resource-limited settings. Outbreaks occur in communities with immunization rates <95%. The disease shows no gender predilection and can affect any age.

Pathophysiology

Measles virus (paramyxovirus family) enters via respiratory epithelium and replicates in lymphoid tissues. Primary viremia at days 3-7 disseminates virus to skin and mucous membranes. Secondary viremia (days 8-12) coincides with symptom onset as viral clearance antibodies develop. The characteristic rash results from T-cell mediated immune response to virus-infected endothelial cells and viral antigens in dermis. Koplik spots appear as viral replication peaks in oral mucosa. Peak viral shedding occurs 2-3 days before rash appearance, with continued respiratory shedding for 4+ days after rash onset.

Clinical Presentation

Measles presents with a 2-4 day prodrome of fever (39-40.5°C), cough, coryza, conjunctivitis (often conjunctival injection without exudate), and malaise. Koplik spots (pathognomonic) appear 1-2 days before rash: tiny white spots with red halos on buccal mucosa opposite molars, described as "grains of white sand on red background." The exanthem begins on the hairline and face, spreading downward to reach trunk by day 2-3 and extremities by day 3-4. Rash initially appears as discrete macules that coalesce into maculopapules, especially on neck and upper chest. Temperatures peak at rash onset then gradually decline over 3-4 days. Rash peaks at day 3-4 and fades over next 3-4 days. Desquamation may occur during fading phase.

Diagnosis

Clinical diagnosis is highly reliable based on characteristic prodrome, Koplik spots, and rash progression. Confirmation testing includes RT-PCR from nasopharyngeal swab or throat swab (most sensitive if performed within 3 days of rash onset), IgM serology, or viral culture. Serology showing IgM antibodies confirms diagnosis if RT-PCR is negative. CBC often shows leukopenia initially, then relative lymphocytosis. Case confirmation requires notification to public health authorities.

Treatment (Age-Specific)

Infants (6-12 months): Supportive care is primary treatment. Acetaminophen dosing: 15 mg/kg/dose every 4-6 hours (maximum 5 doses/24 hours, maximum daily dose 60 mg/kg/day). Maintain hydration with breast milk, formula, or oral rehydration solution. Monitor for complications: fever >40.5°C for >3 days suggests secondary bacterial infection, respiratory symptoms warrant chest exam for pneumonia, neurologic symptoms warrant evaluation for encephalitis.

Vitamin A supplementation (CRITICAL): Reduces complications by 23% and mortality by 12%. Dosing: infants 6-12 months: 100,000 IU once daily on days 1 and 2, then repeat dose at 2-4 weeks. Administer with fat-containing food to maximize absorption. Children >12 months: 200,000 IU once daily for 2 days, then third dose 2-4 weeks later. For severe measles or complications, give 200,000 IU regardless of age.

Children 1-8 years: Acetaminophen 15 mg/kg/dose every 4-6 hours or ibuprofen 10 mg/kg/dose every 6-8 hours for fever management (maximum 40 mg/kg/day for ibuprofen). Vitamin A dosing: 200,000 IU daily for 2 days, repeat dose 2-4 weeks later. For secondary bacterial otitis media: amoxicillin-clavulanate 45 mg/kg/day (amoxicillin component) divided twice daily for 10 days. For secondary bacterial pneumonia: azithromycin 10 mg/kg/day once daily for 5 days or amoxicillin-clavulanate as above.

Older Children (8+ years): Supportive care with acetaminophen 325-650 mg every 4-6 hours or ibuprofen 400-600 mg every 6-8 hours. Continue vitamin A supplementation at pediatric dosing. Secondary infections managed as above. Antiviral agents (ribavirin) may be considered in immunocompromised children (CD4 <200/mm³); consult pediatric infectious diseases.

Immunocompromised children: Require close monitoring and consideration of IV immunoglobulin (IVIG) 400 mg/kg as single dose within 6 days of exposure if not previously vaccinated. IVIG 2 g/kg may be given to modify infection severity within 72 hours of exposure.

Prognosis

Most immunocompetent children recover completely within 7-10 days. Complications occur in 1-2% of vaccinated breakthroughs but higher in unvaccinated populations. Pneumonia (1-6% of cases), otitis media (7%), encephalitis (1 per 1000), and subacute sclerosing panencephalitis-SSPE (4 per 100,000 infections, typically 7-10 years post-infection) are serious complications. Mortality is <0.1% in well-nourished, immunocompetent children but exceeds 5% in malnourished or immunocompromised populations.

When to See a Pediatric Dermatologist

Dermatologic consultation helps confirm diagnosis if presentation is atypical. Secondary bacterial skin infections require assessment. Complications warrant specialist evaluation. Children with suspected SSPE years after measles require neurologic and dermatologic assessment.

FAQ

References